Microdosing Ketamine for Health & Longevity

Evidence Review created on 09/30/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Ketamine Microdosing, Low-Dose Ketamine, Very Low-Dose Sublingual Ketamine, Sublingual Ketamine, Oral Ketamine, Ketamine, Ketamine Hydrochloride, Ketalar

Motivation

Ketamine is an anesthetic medicine that has been used in operating rooms for more than half a century. Microdosing ketamine means taking small, repeated oral or sublingual doses, usually as pharmacy-made lozenges or dissolving tablets, at levels meant to stay below the dreamlike, detached state that larger doses produce. At these doses, ketamine is thought to work by briefly shifting a major chemical signaling system in the brain and encouraging new connections between nerve cells.

Interest began when researchers studied single ketamine infusions in people with severe depression that had not responded to standard medicines. Home-based regimens have since spread through telehealth services and specialty pharmacies, and some health-focused adults now take small doses hoping for steadier mood and a brain that stays adaptable with age.

This review examines what controlled and observational studies show about small, repeated doses of ketamine taken outside the clinic, how those findings apply to adults pursuing long-term health, and what is known about its risks. It also covers dosing approaches, interactions with other substances and monitoring.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and scientific articles that give a high-level overview of ketamine microdosing, low-dose ketamine and their evidence base.

Content from Rhonda Patrick, Chris Kresser, Life Extension and Lifespan.io was not included: none of these platforms has content that discusses ketamine or ketamine microdosing in substantial depth (only brief mentions, a short entry within a broad depression protocol, or a directory listing).

Grokipedia

Ketamine

An encyclopedic overview of ketamine’s chemistry, pharmacology, medical and psychiatric uses and recreational harms; useful background, though it offers no dedicated analysis of microdosing.

Examine

Ketamine

A brief summary describing ketamine as a fast-acting anesthetic with pain-relieving, anti-inflammatory and antidepressant properties, linked to study summaries; it gives no microdosing-specific dosing analysis.

ConsumerLab

No ConsumerLab article on ketamine or ketamine microdosing was found. ConsumerLab does not typically cover prescription medications, and ketamine is a controlled prescription drug rather than a dietary supplement.

Systematic Reviews

This section lists systematic reviews and meta-analyses on low-dose, oral and repeated ketamine and on its principal risks.

Mechanism of Action

Ketamine blocks the NMDA receptor (N-methyl-D-aspartate receptor, a glutamate-activated channel central to learning and memory). At low doses it preferentially quiets inhibitory interneurons (nerve cells that damp down activity), causing a brief surge of glutamate that stimulates AMPA receptors (fast-acting glutamate receptors). This releases BDNF (brain-derived neurotrophic factor, a growth factor for neurons) and activates mTOR (mechanistic target of rapamycin, a cell-growth signaling hub); in rats this rapidly increased synapse formation in the prefrontal cortex (Li et al., 2010).

Competing explanations exist. In mice, the metabolite (2R,6R)-hydroxynorketamine produced antidepressant effects without blocking NMDA receptors (Zanos et al., 2016). In humans, pretreatment with naltrexone (an opioid-receptor blocker) blunted the antidepressant response, implicating opioid signaling (Williams et al., 2018). A trial giving ketamine under surgical anesthesia, so patients could not perceive it, found no advantage over placebo, suggesting expectancy contributes (Lii et al., 2023).

Pharmacologically, ketamine is moderately selective: its main target is the NMDA receptor, with weaker opioid and monoamine actions. It is fat-soluble and distributes rapidly to the brain. Plasma half-life is about 2–3 hours. It is metabolized mainly by CYP3A4 and CYP2B6 (liver enzymes that break down many drugs) to norketamine and hydroxynorketamine. Extensive first-pass liver metabolism makes oral bioavailability (the fraction reaching the bloodstream) poor, while sublingual absorption reaches roughly 30% (Peltoniemi et al., 2016); swallowed doses therefore deliver relatively more norketamine.

Historical Context & Evolution

Ketamine was synthesized in 1962 as a shorter-acting, safer alternative to phencyclidine and approved in the United States in 1970 as an anesthetic. Its reliability without suppressing breathing made it a battlefield and emergency staple, while its dissociative effects (feeling detached from one’s body and surroundings) led to recreational use from the 1980s onward.

Its consideration for mental health began with a 2000 placebo-controlled crossover study in seven depressed patients, in which a single 0.5 mg/kg infusion lowered depression scores by 14 points within 72 hours versus no change with saline (Berman et al., 2000). A 2006 trial in 18 treatment-resistant patients reported response in 71% the day after infusion (Zarate et al., 2006). In 2013, a Brazilian case series described repeated 10 mg sublingual doses, the origin of “microdosing” protocols (Lara et al., 2013). Esketamine, the mirror-image S-form, was approved as a nasal spray in 2019, and telehealth prescribing of compounded home ketamine expanded from 2020, prompting a 2023 safety alert on compounded oral products from the FDA (US Food and Drug Administration).

Scientific opinion has shifted in both directions. Supportive evidence grew from oral and extended-release tablet trials and from interest in aging biomarkers. Counterevidence emerged from dose-ranging trials in which very low doses did not clearly outperform placebo (Fava et al., 2020) and from the anesthesia-masked trial (Lii et al., 2023), which reopened the question of how much benefit depends on expectancy. The value of small home doses in people without depression remains largely untested.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Depressive Symptoms

Repeated low oral doses (0.5–1.25 mg/kg, two to three times weekly) reduced depression scores versus placebo in a meta-analysis of eight RCTs (randomized controlled trials) and in a separate pooled analysis of 592 patients. Trials were small, and two missed their primary endpoints, including an industry-run prolonged-release tablet trial (sponsor HMNC Brain Health). All participants had diagnosed, often treatment-resistant depression; no trial has tested 10–25 mg sub-perceptual doses or non-depressed adults seeking optimization, and very low intravenous doses underperformed in dose-ranging trials (Fava et al., 2020).

Magnitude: Standardized mean difference (effect size in standard-deviation units; 0.5 is moderate) −0.62 (95% CI [confidence interval, the range likely to contain the true value] −0.85 to −0.39) across 8 RCTs with 414 patients (Shenoy et al., 2026); NNT (number needed to treat for one additional responder) 4.9 across 592 patients (Silberbauer et al., 2026); remission 27.3% vs 0% after 21 days of 1 mg/kg three times weekly (Domany et al., 2019); prolonged-release tablets missed the day-21 endpoint (Walter et al., 2026).

Medium 🟩 🟩

Prevention of Depressive Relapse

In the only placebo-controlled maintenance trial, people who responded to extended-release oral ketamine tablets were randomized to 30–180 mg or placebo twice weekly for 12 weeks, mostly dosing at home, and relapse fell in a dose-dependent way. The trial was funded by the tablet’s developer, Douglas Pharmaceuticals, and enrolled only initial responders. A systematic review of maintenance regimens reached a similar conclusion from mostly uncontrolled data (Smith-Apeldoorn et al., 2022).

Magnitude: Relapse 42.9% with 180 mg vs 70.6% with placebo over 13 weeks; MADRS (Montgomery–Åsberg Depression Rating Scale, a 0–60 clinician-rated depression score) difference −6.1 points (Glue et al., 2024).

Low 🟩

Reduction of Suicidal Thoughts

A single 0.5 mg/kg intravenous infusion reduced suicidal thoughts within one day and for up to a week in an individual-patient meta-analysis, partly independently of mood change. No trial has tested repeated small oral or sublingual doses for this outcome, so the evidence is indirect.

Magnitude: Cohen’s d (effect size; 0.5 moderate, 0.8 large) 0.48–0.85 after one infusion (Wilkinson et al., 2018); no figure exists for microdoses.

Reduction of Anxiety

In refractory social and generalized anxiety, ascending subcutaneous (under-the-skin) doses reduced anxiety within an hour, with minor effects at 0.25 mg/kg and larger ones at 0.5–1 mg/kg (Glue et al., 2017). An uncontrolled at-home sublingual study run by the telehealth company Mindbloom also reported improvement.

Magnitude: Response odds ratio (odds of responding versus control) 28.94 (95% CI 3.45–242.57) for social anxiety but 2.03 (95% CI 0.67–6.15, not significant) for PTSD across six small RCTs (Whittaker et al., 2021); 62.9% reported ≥50% anxiety improvement without a control group (Hull et al., 2022).

Reduced Alcohol Consumption

Three weekly 0.8 mg/kg infusions combined with psychological therapy increased abstinent days at six months in 96 people with severe alcohol use disorder, while relapse rates did not differ. Doses exceeded microdoses and were clinic-administered.

Magnitude: Days abstinent +10.1 percentage points (95% CI 1.1–19.0) versus placebo at 6 months (Grabski et al., 2022).

Chronic Pain Relief ⚠️ Conflicted

Oral ketamine is prescribed off-label for neuropathic (nerve-damage) pain, and low intravenous doses relieve acute pain comparably to morphine (Balzer et al., 2021). A 2025 Cochrane review found no clear chronic-pain reduction with oral ketamine in small trials. Net: no reliable chronic-pain benefit is shown for low oral doses.

Magnitude: Mean difference −9.80 points on a 0–100 pain scale (95% CI −23.55 to 3.95; low certainty) versus placebo in the short term (Ferraro et al., 2025).

Improved Cognitive Function ⚠️ Conflicted

In depressed patients, attention and memory improved after serial 0.5 mg/kg infusions in open-label studies, largely tracking mood improvement, and very-low-dose sublingual users reported clearer thinking (Lara et al., 2013). Acute doses transiently impair working memory. Net: no cognitive gain is demonstrated in healthy adults.

Magnitude: Improvements of Cohen’s d 0.37–0.79 in attention and memory after seven infusions in 38 patients, without a control group (Phillips et al., 2022).

Speculative 🟨

Enhanced Neuroplasticity

In rats, ketamine increased prefrontal synapses via mTOR (Li et al., 2010); in depressed patients, one infusion raised BDNF and deep-sleep slow waves (Duncan et al., 2013). The basis is mechanistic only; microdoses are untested.

Slower Epigenetic Aging

In a 20-patient uncontrolled pilot by TruDiagnostic and Wild Health, companies selling epigenetic tests, six infusions lowered three epigenetic clocks (DNA-methylation age estimates) (Dawson et al., 2025). The basis is unvalidated biomarkers only.

Reduced Inflammation

Intraoperative ketamine lowered early post-surgical IL-6 (interleukin-6, an inflammatory signaling protein) in a meta-analysis (Dale et al., 2012). Effects of small repeated doses on chronic low-grade inflammation are unstudied.

Enhanced Creativity

Microdosing users describe more creative, flexible thinking in daily life. The basis is anecdotal only; no controlled trial has measured creativity after ketamine microdoses in healthy adults.

Benefit-Modifying Factors

  • Genetic polymorphisms: Met/Met carriers of BDNF Val66Met (a variant reducing BDNF release) did not respond to 0.5 mg/kg in one RCT (Chen et al., 2021); a cohort from Braxia Health, a ketamine clinic operator, found no genetic predictor (Rodrigues et al., 2024).
  • Baseline biomarkers and severity: Benefits were larger in studies requiring prior antidepressant failures (Price et al., 2022); adults without depression have little room to improve. Higher baseline white-cell counts tracked response to prolonged-release tablets (Colla et al., 2024).
  • Sex: In a 99-patient dose-ranging RCT, antidepressant response did not differ between women and men or between pre- and postmenopausal women (Freeman et al., 2019).
  • Pre-existing conditions: Improvement at day 3 was smaller in bipolar than unipolar depression (Xu et al., 2016). Anxiety disorders respond in a dose-dependent way, and people on higher-dose benzodiazepines (sedative anti-anxiety drugs) showed blunted next-day response (Feeney et al., 2022).
  • Age: In veterans aged 55–72, 0.1 and 0.25 mg/kg arms were stopped for inferiority while 0.5 mg/kg worked (Lijffijt et al., 2022); esketamine showed no benefit in those 75 or older in a trial run by its manufacturer Janssen (Ochs-Ross et al., 2020).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Dissociation and Perceptual Disturbances

Dissociation (feeling detached from one’s body or surroundings), altered perception and transient psychosis-like symptoms rise with dose and peak within an hour. A meta-analysis of 36 placebo-controlled studies in healthy volunteers found large increases with intravenous doses. Oral dosing blunts peak levels, and a prolonged-release tablet produced almost no dissociation. Adults over 60 given 0.5–1 mg/kg during surgery reported more hallucinations and nightmares (Avidan et al., 2017).

Magnitude: Psychosis-like symptom increase with a standardized mean difference of 1.50 (95% CI 1.23–1.77) after intravenous ketamine in healthy volunteers (Beck et al., 2020); dissociation-scale change of 0.7 vs 29.6 points for oral prolonged-release ketamine 240 mg vs nasal esketamine 84 mg (Walter et al., 2026).

Dizziness, Headache, Nausea and Sedation

These are the most frequent adverse events with oral and sublingual dosing and usually resolve within about four hours. In a placebo-controlled dose-ranging study of immediate-release oral ketamine 40–240 mg in healthy volunteers, sponsored by the formulation’s developer Neurocentrx Pharma, adverse events were far more frequent than after placebo. In a long-term esketamine extension funded by its manufacturer Janssen, each occurred in at least 20% of participants.

Magnitude: 80 mild-to-moderate adverse events after oral ketamine vs 5 after placebo in 19 volunteers (Qureshi et al., 2025); headache, dizziness, nausea and sleepiness each ≥20% over a mean 31.5 months of esketamine (Zaki et al., 2023).

Transient Rise in Blood Pressure and Heart Rate

Ketamine stimulates the sympathetic nervous system (the body’s fight-or-flight network), raising blood pressure and pulse for one to two hours after dosing. At the standard 0.5 mg/kg infusion the rise is small and does not diminish across repeated sessions, but people with hypertension show higher peaks. Oral extended-release tablets produced no meaningful blood-pressure change in a controlled trial.

Magnitude: Mean peak rise of +3.3/+3.2 mmHg at 30 minutes over 684 infusions (Riva-Posse et al., 2018); larger transient rises at 0.5–1.0 mg/kg than at lower doses (Fava et al., 2020); no change with oral tablets over 13 weeks (Glue et al., 2024).

Medium 🟥 🟥

Bladder and Urinary Tract Damage

Ketamine and its metabolites injure the bladder lining, causing ketamine uropathy (urinary tract damage): frequency, urgency, pain, shrunken bladder capacity and sometimes hydronephrosis (kidney swelling from obstructed urine flow). Evidence comes from recreational users at doses far above microdoses. Esketamine trials report more lower urinary tract symptoms but no severe bladder disease at depression doses (Nikayin et al., 2022). Stopping ketamine is required for recovery.

Magnitude: Among affected users (45 studies, 4,921 patients), urinary frequency 77.1%, suprapubic pain (pain above the pubic bone) 60.4% and hydronephrosis 30.2% (Chan et al., 2022); incidence at microdoses is unknown.

Low 🟥

Misuse, Dependence and Tolerance ⚠️ Conflicted

Ketamine is a Schedule III controlled substance (a US category for drugs with moderate abuse potential), and tolerance develops with frequent use. A 2026 systematic review found minimal misuse under supervision, with cases mainly in unmonitored settings. Net: risk appears low under supervision and is unquantified for unsupervised home use.

Magnitude: Risk rises with unsupervised access, higher doses and dosing more often than weekly; the literature reports no incidence figure for therapeutic at-home use (Vasudeva et al., 2026).

Liver Injury

Prolonged, repeated infusions have caused drug-induced liver injury with liver enzyme rises that resolved within two months of stopping. Data are case reports at exposures far above microdoses.

Magnitude: 3 of 6 patients developed enzyme elevations of at least 3 times the upper limit of normal during a second 100-hour infusion (Noppers et al., 2011).

Bile Duct Injury (Cholangiopathy)

Heavy recreational use has caused ketamine cholangiopathy (widening of the bile ducts with impaired bile flow), with upper abdominal pain and abnormal liver tests. Evidence comes only from case series in recreational users (Teymouri et al., 2024); widening tracked duration of use and improved with abstinence.

Magnitude: Common bile duct widening in 18 of 26 (69%) ketamine users imaged for abnormal liver tests or abdominal pain (Yu et al., 2014); incidence at microdoses is unknown.

Cognitive Impairment with Frequent Use ⚠️ Conflicted

In a one-year cohort, frequent recreational users showed spatial and recognition memory decline in proportion to increasing use; infrequent users did not. Therapeutic courses in depression show stable or improved cognition (Singh et al., 2024). Net: harm is documented at heavy recreational exposure, not at therapeutic low doses.

Magnitude: Decline in memory performance scaled with increasing use over 12 months among frequent users only; the study reports no effect size applicable to low doses (Morgan et al., 2010).

Mood Worsening with Heavy Use

In the same one-year cohort, both frequent and formerly heavy users showed rising depression scores, suggesting sustained heavy use may worsen mood. Evidence is observational and limited to recreational users.

Magnitude: Depression scores increased over 12 months in frequent and abstinent former users; the study reports no figure applicable to low doses (Morgan et al., 2010).

Speculative 🟨

Neurotoxicity

High-dose NMDA blockers cause Olney lesions (small fluid-filled holes in neurons) in rodent brains; no human evidence exists at therapeutic or microdoses. The basis is animal data only.

Opposing mTOR-Targeting Longevity Strategies

Ketamine transiently activates mTOR, the growth pathway that rapamycin and caloric restriction suppress in longevity protocols. Whether intermittent activation offsets such strategies is unknown; the basis is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: Carriers of CYP2B6*6 (a reduced-function variant of the enzyme) cleared ketamine up to 68% more slowly, and lower clearance was associated with more adverse effects (Li et al., 2015).
  • Baseline biomarkers: People with hypertension reach higher blood-pressure peaks (Riva-Posse et al., 2018). Elevated liver enzymes or abnormal urinalysis at baseline leave less margin for liver or bladder injury.
  • Sex: Women reported numerically more headache (12% vs 6%) and nausea (10% vs 6%) than men, without statistical significance (Freeman et al., 2019).
  • Pre-existing conditions: Psychotic disorders, substance use disorders, bladder disease, liver disease, uncontrolled hypertension and aneurysm (a ballooned artery wall) raise the risks of psychiatric worsening, misuse, uropathy, liver injury and cardiovascular events respectively.
  • Age: Age reduced ketamine clearance and, with CYP2B6*6, explained 60% of variation in blood levels (Li et al., 2015); adults over 60 had more hallucinations and nightmares after 0.5–1 mg/kg (Avidan et al., 2017).

Key Interactions & Contraindications

Prescription drugs

  • Benzodiazepines (lorazepam, alprazolam, clonazepam): Caution. Additive sedation and falls; higher doses blunted next-day antidepressant response (Feeney et al., 2022). Mitigation: no benzodiazepine on dosing evenings, with any change agreed with the prescriber.
  • Opioids (oxycodone, morphine, fentanyl): Caution. Additive sedation and respiratory depression (slowed breathing). Mitigation: co-dosing only under medical supervision, not at home.
  • Opioid antagonists (naltrexone, including low-dose naltrexone): Monitor. Pretreatment blunted ketamine’s antidepressant effect in two trials (Williams et al., 2018; Jelen et al., 2025). Mitigation: reassessing the need for both, or separating timing.
  • CYP3A4 inhibitors (clarithromycin, grapefruit juice): Monitor. Clarithromycin raised oral S-ketamine exposure 2.6-fold (Hagelberg et al., 2010) and grapefruit juice 3.0-fold (Peltoniemi et al., 2012), intensifying sedation and dissociation. Mitigation: pausing or reducing doses during exposure.
  • CYP2B6 inhibitors (ticlopidine, clopidogrel): Monitor. Ticlopidine raised oral S-ketamine exposure 2.4-fold and increased drowsiness (Peltoniemi et al., 2011). Mitigation: a lower starting dose.
  • Lamotrigine: Monitor. Attenuated ketamine’s perceptual and psychosis-like effects in healthy volunteers while enhancing its immediate mood elevation (Anand et al., 2000); the effect on antidepressant benefit is unknown. Mitigation: tracking response with mood scores.
  • Stimulants and MAOIs (monoamine oxidase inhibitors, an older class of antidepressants; amphetamine, methylphenidate, phenelzine): Caution. Additive blood-pressure and heart-rate rise. Mitigation: blood-pressure checks before and 60 minutes after dosing.
  • Rapamycin (sirolimus): Monitor. A 6 mg dose before ketamine prolonged the antidepressant effect at two weeks in one crossover RCT (Abdallah et al., 2020), contrary to predicted blockade. Mitigation: consistent relative timing.

Over-the-counter medications

  • Dextromethorphan (cough suppressants): Caution. Additive NMDA blockade, with dizziness and dissociation. Mitigation: no use on dosing days.
  • Sedating antihistamines (diphenhydramine, doxylamine): Caution. Additive sedation and psychomotor impairment. Mitigation: a 12-hour gap from ketamine doses.
  • Decongestants (pseudoephedrine, phenylephrine): Caution. Additive blood-pressure rise. Mitigation: no use on dosing days, or blood-pressure monitoring.

Supplements

  • St John’s wort: Monitor. Cut oral S-ketamine exposure by 58% (Peltoniemi et al., 2012), risking loss of effect. Mitigation: not combining, or keeping intake constant.
  • Cannabidiol (CBD): Monitor. Inhibits several CYP enzymes and may raise ketamine levels while possibly reducing dissociation; a formal interaction trial is planned (NCT07462559). Mitigation: a low starting ketamine dose.
  • Sedating supplements (kava, valerian, high-dose melatonin): Caution. Additive sedation. Mitigation: no use on dosing evenings.
  • Magnesium and zinc (natural NMDA modulators): Monitor. Theoretical additive NMDA blockade, without clinical harm reported. Mitigation: stable supplement doses during a course.
  • Yohimbine and high-dose caffeine: Caution. Additive blood-pressure and heart-rate rise. Mitigation: a 6-hour gap from dosing.

Other interventions

  • Alcohol and cannabis: Avoid. Additive sedation, dissociation, nausea and impaired coordination. Mitigation: abstinence on dosing days.
  • Driving and operating machinery: Avoid. Impaired attention and coordination. Mitigation: no driving until the next day after restful sleep, as esketamine labeling requires.
  • Psychotherapy: No safety concern (potentiating). Ketamine plus therapy produced the largest abstinence gain in alcohol use disorder (Grabski et al., 2022). Mitigation: not applicable.

Populations who should avoid Microdosing Ketamine:

  • History of psychosis, schizophrenia-spectrum disorder, or bipolar I disorder with mania in the past 12 months
  • Current or past substance use disorder (moderate or severe by DSM-5, the standard psychiatric diagnostic manual), especially involving ketamine, stimulants or alcohol
  • Blood pressure above 140/90 mmHg before dosing despite treatment
  • Aneurysmal vascular disease (ballooned artery walls in the brain, aorta or peripheral arteries), arteriovenous malformation (abnormal artery-vein tangle) or prior intracerebral hemorrhage (bleeding within the brain), all contraindications on esketamine labeling
  • Myocardial infarction (heart attack) within the past 6 weeks, unstable angina (chest pain at rest), or heart failure NYHA (New York Heart Association) class III–IV
  • Pregnancy, planned pregnancy or breastfeeding
  • Liver impairment Child-Pugh class C (severe cirrhosis), or liver enzymes above 3 times the upper limit of normal
  • Interstitial cystitis (chronic bladder inflammation) or unexplained lower urinary tract symptoms
  • Age under 18

Risk Mitigation Strategies

  • Medical oversight and screening: Baseline psychiatric, cardiovascular, liver and urinary screening by a prescriber before the first dose reduces cardiovascular events, psychiatric destabilization and misuse.
  • Low start, slow titration: Protocols start at 5–10 mg sublingual and rise by 5–10 mg per session only if needed, staying below noticeable dissociation, which limits dissociation, dizziness and falls.
  • Spaced dosing: One session every 2–7 days, without daily use, reduces tolerance, dependence and cumulative bladder exposure.
  • Blood pressure checks: Readings before and 60 minutes after the first three doses, with dosing skipped above 140/90 mmHg, prevent hypertensive surges.
  • Safe setting: Dosing seated or lying down, no stairs for 2 hours and no driving until the next day prevent falls and accidents.
  • Misuse safeguards: A single prescriber, dose logs, locked storage and monthly review of any urge to raise dose or frequency guard against dependence and diversion.
  • Urinary vigilance: Stopping at the first new urinary frequency, urgency, pain or blood in urine, plus urinalysis every 3 months, prevents progression of ketamine uropathy.
  • Liver monitoring: Liver enzymes at baseline, at 4 weeks and every 3–6 months detect drug-induced liver or bile duct injury early.
  • Interaction hygiene: No grapefruit, alcohol, benzodiazepines or dextromethorphan on dosing days prevents overexposure and excess sedation.

Therapeutic Protocol

  • Very-low-dose sublingual (“microdosing”): 10 mg ketamine held sublingually for about 5 minutes, then swallowed, every 2–3 days or weekly, as described by Diogo Lara in Brazil (Lara et al., 2013) and continued by Mitchell Liester in Colorado.
  • Low-dose telehealth lozenges: Joyous, a US telehealth company, popularized daily 15–120 mg troches (compounded lozenges) held buccally (against the cheek) for about 15 minutes, then discarded, with remote support; its protocols are unpublished as controlled trials.
  • Low-dose oral per-kilogram dosing: 0.5–1 mg/kg (about 35–70 mg at 70 kg) orally two to three times weekly for three weeks, the regimen of academic trials such as Domany’s in Tel Aviv (Domany et al., 2019).
  • Extended-release tablets (investigational): R-107, developed by Paul Glue at Otago with Douglas Pharmaceuticals, used 120 mg daily for 5 days, then 30–180 mg twice weekly (Glue et al., 2024); KET01 used 120–240 mg daily (Walter et al., 2026).
  • Clinic-based reference regimens: Intravenous 0.5 mg/kg over 40 minutes or esketamine 56–84 mg nasal spray are the best-studied comparators; they are not microdosing.
  • Time of day: Late afternoon or evening at home, lying down, allows dizziness and sedation to pass before sleep; esketamine labeling bars driving until the next day after restful sleep.
  • Half-life: Ketamine’s plasma half-life is 2–3 hours, but mood effects outlast the drug by days, which is why most protocols space doses every 2–7 days; daily telehealth regimens are the exception.
  • Single versus split doses: One dose per session is standard; split daily dosing is unstudied and adds exposure. Holding sublingual doses 5–15 minutes and discarding the residue limits swallowed drug and norketamine formation.
  • Genetic polymorphisms: CYP2B6*6 carriers clear ketamine more slowly and may need lower starting doses; genotyping is optional because no genotype reliably predicts benefit.
  • Sex: No sex-specific dosing is supported; efficacy and tolerability did not differ between women and men in dose-ranging data (Freeman et al., 2019).
  • Age: Older adults clear ketamine more slowly, favoring the lowest starting dose, yet very low intravenous doses were inferior in adults 55–72 (Lijffijt et al., 2022), so benefit at microdoses is least certain in this group.
  • Baseline biomarkers: Higher baseline white-cell counts tracked response to prolonged-release tablets (Colla et al., 2024); a baseline PHQ-9 (Patient Health Questionnaire-9, a 0–27 depression score) anchors titration, while blood pressure below 140/90 mmHg gates each dose.
  • Pre-existing conditions: Controlled hypertension, bipolar disorder on a mood stabilizer, and chronic pain are managed with lower starting doses and closer follow-up; psychosis and active substance use disorder exclude use.

Discontinuation & Cycling

  • Duration: Microdosing is used as short courses or intermittent maintenance, not lifelong therapy; controlled data extend to 13 weeks for oral tablets (Glue et al., 2024), and open-label data to 4.5 years for clinic-supervised esketamine (Zaki et al., 2023).
  • Withdrawal effects: No withdrawal syndrome is documented at therapeutic low doses. Heavy recreational users describe craving, anxiety, low mood and fatigue after stopping.
  • Tapering: Frequency is usually stepped down, for example from twice weekly to weekly to every two weeks, rather than stopped abruptly, because relapse was common after stopping in maintenance trials.
  • Cycling: Many prescribers use 4–8 week courses separated by breaks of several weeks to limit tolerance; this practice has not been tested against continuous dosing.
  • Relapse monitoring: Weekly mood ratings for 4–8 weeks after stopping identify early relapse, which reached 70.6% within 13 weeks among responders switched to placebo (Glue et al., 2024).

Sourcing and Quality

  • Legal status and supply: Ketamine is a prescription-only controlled substance (Schedule III in the United States). Legitimate supply requires a prescriber and a licensed pharmacy.
  • Formulation: Microdoses come as compounded sublingual troches, rapid-dissolving tablets or oral solutions of racemic ketamine hydrochloride (the standard 50:50 mix of both mirror-image forms). Esketamine nasal spray is the only approved psychiatric form; extended-release tablets remain investigational.
  • Compounded product quality: Compounded ketamine is not reviewed by the FDA for safety or potency, and the agency issued a 2023 alert on compounded oral ketamine used at home for psychiatric conditions.
  • What to look for: A state-licensed compounding pharmacy with PCAB (Pharmacy Compounding Accreditation Board) accreditation, batch potency testing, labeled milligram strength per unit, tamper-evident and child-resistant packaging.
  • Reputable sources: Research-grade products come from licensed local compounders, such as Ultimate Care Compounding, which supplies a Western University trial; telehealth services such as Joyous and Mindbloom dispense through partner pharmacies.
  • Avoid illicit supply: Street or online “research chemical” ketamine carries unknown dose and adulteration, including ketamine analogs, and removes medical oversight.

Practical Considerations

  • Time to effect: In depression trials, oral low-dose benefits became significant by the second week of repeated dosing (Nuñez et al., 2020); users of very-low-dose sublingual regimens report effects within days.
  • Common pitfalls: Escalating dose or frequency when effects fade, combining with alcohol or sedatives, dosing before driving, ignoring early urinary symptoms and expecting enhancement without an underlying mood problem.
  • Regulatory status: Racemic ketamine is FDA-approved only as an anesthetic; psychiatric and microdosing use is off-label. Esketamine nasal spray is approved for treatment-resistant depression under a restricted in-clinic program.
  • Cost and accessibility: Telehealth microdosing plans cost roughly US$129–159 per month; generic ketamine itself is inexpensive. Insurers typically cover patented esketamine but not generic home ketamine, creating payer incentives that favor the costlier product.
  • Structural research bias: Because generic ketamine is off-patent, few sponsors fund large trials, while companies developing new tablets or selling services fund much of the recent evidence.

Interaction with Foundational Habits

  • Sleep: Direct, potentiating. A single infusion increased deep slow-wave sleep and BDNF in depressed patients (Duncan et al., 2013), while higher doses can cause vivid dreams or nightmares. Evening dosing lets sedation coincide with sleep; tracking sleep quality detects disruption.
  • Nutrition: Indirect. Grapefruit juice tripled oral S-ketamine exposure (Peltoniemi et al., 2012), making its intake relevant on dosing days; dosing on an empty stomach reduces nausea. No nutrient depletion is documented, and alcohol on dosing days adds sedation.
  • Exercise: None documented directly. Exercise independently raises BDNF and mood, so the effects may be complementary, but dizziness makes workouts unsafe for several hours after dosing; scheduling exercise on non-dosing days or before a dose avoids falls.
  • Stress management: Potentiating. Pairing ketamine with structured therapy or mindfulness-based relapse prevention improved outcomes in alcohol use disorder (Grabski et al., 2022); a calm setting and intention-setting reduce anxiety during dosing.

Monitoring Protocol & Defining Success

Baseline testing establishes safety before the first dose: blood pressure and heart rate, liver enzymes, kidney function, urinalysis, a pregnancy test where relevant, and validated mood and anxiety questionnaires, together with screening for psychosis, bipolar disorder and substance use. Ongoing monitoring follows a fixed cadence: blood pressure before and 60 minutes after each of the first three doses, symptom questionnaires weekly for the first 4 weeks, laboratory tests at 4 weeks, then every 3 months while dosing continues, and urinary symptoms at every session. Success is defined in advance as at least a 50% fall in PHQ-9 or a score below 5, without escalating dose or frequency; no meaningful change after 4–6 sessions signals that the regimen is not working and supports stopping.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure Below 120/80 mmHg at rest Detect ketamine-induced rises Conventional target below 130/80 mmHg; measure seated, before and 60 minutes after early doses
Resting heart rate 50–70 beats per minute Detect sympathetic stimulation Conventional range 60–100; pair with blood pressure
ALT Below 25 U/L Early liver injury ALT = alanine aminotransferase, a liver enzyme; conventional upper limit about 40–55 U/L; no fasting needed; pair with AST (aspartate aminotransferase)
GGT Below 25 U/L Bile-flow (cholestatic) injury GGT = gamma-glutamyl transferase, a liver enzyme; conventional upper limit about 60 U/L; alcohol raises it; morning draw preferred
Urinalysis (blood, white cells, protein) Negative for all Early bladder irritation First-morning midstream sample; repeat if urinary symptoms appear
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Upper urinary tract involvement eGFR = estimated glomerular filtration rate, the kidneys’ filtering capacity; conventional threshold above 60; avoid heavy exercise 24 hours before the draw
PHQ-9 Below 5 Track mood benefit PHQ-9 = Patient Health Questionnaire-9, a 0–27 depression score; conventional cutoff below 10 for non-clinical range; same weekday and time each week
GAD-7 Below 5 Track anxiety benefit GAD-7 = Generalized Anxiety Disorder-7, a 0–21 anxiety score; conventional cutoff below 10; pair with PHQ-9
CYP2B6 genotype (optional, once) No established target; record 1/1, 1/6 or 6/6 Identify slow metabolizers Guides starting dose; does not predict benefit

Qualitative markers

  • Mood stability and emotional resilience across the week
  • Sleep quality, dream intensity and next-morning alertness
  • Energy and motivation on non-dosing days
  • Cognitive clarity, memory and focus
  • Intensity of dissociation or dizziness after each dose
  • New urinary frequency, urgency or discomfort
  • Craving, or any urge to increase dose or frequency

Emerging Research

  • Phase 3 oral ketamine trial: A multicenter trial in India (NCT07839338) will randomize 220 people with major depressive episodes to nine sessions of adjunctive oral ketamine or oral midazolam; primary endpoint is the Hamilton Depression Rating Scale. A positive result would strengthen the case for low-cost oral dosing.
  • Abuse-deterrent oral capsules: A phase 2a trial (NCT07644767) will give 160 people with treatment-resistant bipolar depression 140–280 mg doses (as 70 mg capsules) or placebo three times weekly for up to 7 weeks, including remotely supervised home doses; primary endpoint is adverse events. Sponsor Neurocentrx Pharma develops the product.
  • Oral versus sublingual absorption: A phase 1 crossover study (NCT07683988) in 10 people with major depression will compare how the body absorbs and clears compounded oral and sublingual ketamine to define safe home doses.
  • Interaction with cannabidiol and cobicistat: A phase 1 study (NCT07462559) in 12 healthy volunteers will test how cannabidiol and the CYP3A4 blocker cobicistat change exposure to a 56 mg oral dose; primary endpoint is total drug exposure.
  • Prolonged-release add-on therapy: An open-label phase 2 pilot (NCT07396272) gives 12 people starting antidepressants four 240 mg KET01 doses in one week; primary endpoint is MADRS change at one week.
  • Fatigue beyond mood: A phase 2 trial (NCT05378100) of 0.5 mg/kg ketamine versus midazolam in 110 people with multiple sclerosis fatigue tests a non-mood outcome relevant to vitality; a null result would narrow claimed benefits.
  • Expectancy and blinding: The anesthesia-masked trial found no advantage over placebo when patients could not perceive ketamine (Lii et al., 2023); similar masking in microdose trials could weaken or confirm the case for sub-perceptual doses.
  • Biological aging: The uncontrolled epigenetic-clock pilot (Dawson et al., 2025) needs controlled replication; a systematic review found heterogeneous cognitive effects after ketamine (Kelly et al., 2026).
  • Long-term abuse liability: A 2026 systematic review found low abuse liability only under supervision (Vasudeva et al., 2026); prospective data on unsupervised home microdosing could weaken the safety case.

Conclusion

Microdosing ketamine means taking small, spaced oral doses of an old anesthetic at home in the hope of lifting mood and keeping the brain adaptable. For people with depression, repeated low oral doses have reduced symptoms in several small controlled studies, and a long-acting tablet helped people who had improved stay well. The truly tiny doses sold as microdoses have mostly been judged by patient reports, and very small infusions did not clearly beat a placebo. For health-focused adults without depression, claims about focus, creativity, inflammation and biological aging rest on laboratory work, blood markers and one small study without a comparison group.

The harms are best mapped at higher doses: dreamlike detachment, dizziness, nausea, brief rises in blood pressure and, with heavy or unsupervised use, dependence, memory problems and serious bladder damage. At small, spaced doses these harms appear uncommon, but long-term information on home use is thin, so the balance for people without a mood disorder remains uncertain.

The evidence base is small, often lacks comparison groups, and is shaped by money. Several recent trials were run by companies developing ketamine tablets, the largest home-use study came from a company selling the service, the long-term nasal-spray data came from its manufacturer, and the aging study came from firms selling biological-age tests. Because generic ketamine is cheap and unpatented, few sponsors pay for large trials, while insurers cover a patented nasal version, which tilts research and access toward the costlier product.

Top - Benefits - Risks - Protocol